Mahacef-CV 200 Tablet is a combination antibiotic formulation containing Cefixime 200 mg and Clavulanic Acid 125 mg, indicated for the treatment of a variety of bacterial infections. Cefixime, a third-generation cephalosporin, exhibits broad-spectrum bactericidal activity by inhibiting bacterial cell wall synthesis, effectively targeting both Gram-positive and Gram-negative pathogens. Clavulanic Acid, a beta-lactamase inhibitor, enhances the efficacy of Cefixime by preventing enzymatic degradation of the antibiotic, thereby overcoming resistance in beta-lactamase-producing bacteria. This synergistic combination is particularly useful in managing respiratory tract infections, urinary tract infections, otitis media, and skin and soft tissue infections caused by susceptible organisms. Mahacef-CV 200 is administered orally, with dosage and duration tailored according to the severity and type of infection, as well as patient-specific factors such as age and renal function. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and abdominal discomfort, while hypersensitivity reactions are rare but warrant immediate medical attention. Caution is advised in patients with a history of penicillin or cephalosporin allergy. Mahacef-CV 200 Tablet should be prescribed based on susceptibility patterns and clinical judgment to ensure optimal therapeutic outcomes and minimize the risk of antimicrobial resistance.